Clinical trials
Atrophy clinical trials
Below are recruiting atrophy clinical trials, each written for real people, not researchers. We’re tracking 272 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05747261RecruitingPhase 1/Phase 2
Single-dose gene therapy for children with spinal muscular atrophy
This trial tests a one-time gene therapy given through a vein to add a working SMN gene in children with spinal muscular atrophy (SMA). It mainly looks at safety first, and also checks early signs that treatment helps the disease.
MinskAges Up to 8 months - NCT05789758Recruiting
Study of Spinraza in pregnancy for 5q spinal muscular atrophy
This study looks at how Spinraza (nusinersen) taken during or before pregnancy affects people with 5q spinal muscular atrophy (SMA) and the health of their babies. It mainly fits those who were pregnant and received Spinraza around the time of conception or during pregnancy.
Palo Alto, CaliforniaAges 18–54 - NCT05824169RecruitingPhase 1/Phase 2
Gene therapy for babies with severe spinal muscular atrophy
This early-stage study tests whether a one-time gene therapy can safely improve outcomes for babies with the most severe type of spinal muscular atrophy (SMA type 1). It focuses on safety and early signs of benefit, and participation requires specific genetic and health criteria.
BeijingAges birth–6 months - NCT05861999RecruitingPhase 4
Risdiplam for young children with SMA after gene therapy plateau
This trial studies whether risdiplam is safe and helpful for children under 2 with spinal muscular atrophy (SMA) whose function has leveled off or declined after gene therapy. It may be an option if you saw benefits from gene therapy but then noticed a stop or setback in key abilities.
Little Rock, ArkansasAges 3 months–2 years - NCT05861986RecruitingPhase 4
Risdiplam for very young children after gene therapy for SMA
This trial studies whether risdiplam, given early after gene therapy, is safe and helps children with spinal muscular atrophy (SMA) keep improving or stay stable. It focuses on children under 2 years old who already received gene therapy and need to meet timing and health requirements.
Little Rock, ArkansasAges 3 months–2 years - NCT05866419Recruiting
Implantable device for delivering Spinraza through the spine
This trial tests a surgically implanted port and catheter system that delivers Spinraza (nusinersen) into the fluid around the spinal cord, using a more direct route than repeated spinal taps. It may help people with spinal muscular atrophy (SMA) who can’t safely or comfortably get repeated lumbar punctures (spinal taps).
Phoenix, ArizonaAges 3 years+ - NCT05953090Recruiting
Vaginal irritation study with device use and long follow-up
This trial studies a treatment for long-lasting vaginal/vulvar irritation caused by conditions like vaginal atrophy or certain skin conditions of the vulva. You would try the study product/device and be followed over time to see how symptoms recover.
Birmingham, AlabamaAges 18 years+ - NCT06072105Recruiting
Medical decisions in multiple system atrophy: a study in Austria
This study looks at how medical decisions are made for people with multiple system atrophy (MSA). It includes both people with MSA and their unpaid caregivers who live in Austria and speak German. Participants and caregivers will share their experiences through online interviews to help improve future care.
Innsbruck, AustriaAges 30 years+ - NCT06169046RecruitingPhase 2
Clenbuterol for spinal and bulbar muscular atrophy
This study tests if clenbuterol (a medication that may help strengthen muscles) can improve symptoms in people with spinal and bulbar muscular atrophy (SBMA, also called Kennedy's disease). It compares clenbuterol to a placebo (a dummy pill) over several months.
Padova, PDAges 18–75 - NCT06197568RecruitingPhase 2
Study of AZU-101 cream for vaginal dryness in menopause
This study tests an experimental vaginal cream (AZU-101) for postmenopausal women who have vaginal dryness and pain during sex. The goal is to see if it can improve these symptoms without the risks of hormone treatments.
Saint Paul, MinnesotaAges 45–60 - NCT06253104Recruiting
Tracking muscle changes in acute heart failure
This study measures how thigh muscles change in people hospitalized with severe heart failure. It aims to understand muscle loss during this condition and how it relates to recovery.
Boston, MassachusettsAges 18–100 - NCT06321965Recruiting
Study of SMA in Children on SMN-Boosting Therapies
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
Bron, RhoneAges birth–16 years - NCT06394232RecruitingPhase 1/Phase 2
Testing a cell therapy for advanced dry AMD with geographic atrophy
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
Jālna, MaharashtraAges 50–100 - NCT06396325Recruiting
Active video game trial for arm strength in kids with SMA
This trial tests whether playing active video games (exergaming) with your arms can help children and teens with spinal muscular atrophy improve their arm strength and function. If you join, you'll play specially designed games for a period of time, and researchers will see if it makes a difference.
Calgary, AlbertaAges 8–18 - NCT06421831RecruitingPhase 1/Phase 2
Gene therapy trial for spinal muscular atrophy type 3
This trial is testing a one-time gene therapy drug for people with SMA type 3. The goal is to see if it can safely improve muscle function and strength.
Beijing, Beijing MunicipalityAges 2 years+ - NCT06532474Recruiting
Muscle function study in SMA patients on SMN therapies
This study looks at how muscles work in children and young adults with spinal muscular atrophy (SMA) who are taking or starting SMN-directed therapies (like Evrysdi, Spinraza, or Zolgensma). It aims to understand the body's response to these treatments, which could help improve future care.
Memphis, TennesseeAges 5–20 - NCT06500754Recruiting
Persistent intestinal damage in celiac disease on strict diet
This study looks at why some adults with celiac disease still have damage to their small intestine even after strictly avoiding gluten. It aims to understand persistent villous atrophy and could help improve long-term care for people like you.
Terrassa, BarcelonaAges 20–80 - NCT06555419RecruitingPhase 1
How Nusinersen works with ThecaFlex DRx system
This study looks at how a medicine called Nusinersen (Spinraza) works in the body when given through a new device called ThecaFlex DRx. It is for people with spinal muscular atrophy who are already on a steady dose of Nusinersen and are part of the main PIERRE study.
Orange, CaliforniaAges 3 years+ - NCT06557460RecruitingPhase 2
Cell implant for advanced dry age-related macular degeneration
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
Beverly Hills, CaliforniaAges 55–90 - NCT06635148RecruitingPhase 2
Long-term study for geographic atrophy treatment
This study is for people who already took part in a previous trial for geographic atrophy (a late stage of dry age-related macular degeneration) and received the study drug or a sham. It looks at the long-term safety of the treatment over time.
Tucson, ArizonaAges 60 years+ - NCT06779773Recruiting
Study of avacincaptad pegol (Izervay) for geographic atrophy
This study looks at how avacincaptad pegol (brand name Izervay) works in real-world medical practice for people with geographic atrophy, a form of age-related macular degeneration that causes vision loss. If your doctor has already decided to treat you with this medicine, you may be able to join.
Phoenix, ArizonaAges Any age - NCT06831500RecruitingPhase 1/Phase 2
Study on carbidopa/levodopa ratio for low blood pressure in MSA-P and Parkinson's
This study tests whether adjusting the ratio of carbidopa and levodopa (medications used for Parkinson's) can help reduce dizziness or fainting from low blood pressure when standing up, in people with Multiple System Atrophy (Parkinsonian type) or Parkinson's disease.
Lausanne, Canton of VaudAges Any age - NCT06848231RecruitingPhase 2
Study of YA-101 for multiple system atrophy
This trial tests if a new oral medication, YA-101, can help people with multiple system atrophy (MSA), a rare brain condition. It aims to see if the drug is safe and works for both types of MSA (parkinsonian and cerebellar).
Los Angeles, CaliforniaAges 30 years+ - NCT06862596RecruitingPhase 2/Phase 3
Mexiletine for spinal and bulbar muscular atrophy
This trial tests whether mexiletine hydrochloride can help men with spinal and bulbar muscular atrophy (SBMA) by improving muscle strength and function. It may be an option if you have mild to moderate symptoms and meet heart and medication safety checks.
Bunkyō CityAges 18–80
Hear when a new Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atrophy?
- Yes. Clin2 currently lists 272 recruiting atrophy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atrophy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atrophy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.